Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | HPGD | P15428 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2900606 | 0.86 | ALDH1A1 (0.44) | ALDH1A1HPGDSMN1; SMN2KDM4EFFAR4 | |
| SCHEMBL5752058 | 0.82 | POLB (0.42) | SMN1; SMN2MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL29352953 | 0.81 | MAPK1 (0.41) | ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL3852592 | 0.80 | ALDH1A1 (0.43) | ALDH1A1HPGDSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL537673 | 0.79 | MAPK1 (0.42) | ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL254039 | 0.78 | POLB (0.44) | ALDH1A1HPGDSMN1; SMN2KDM4EFFAR4 | |
| SCHEMBL77207 | 0.78 | HSP90AA1 (0.55) | ALDH1A1HPGDSMN1; SMN2KDM4EFFAR4 | |
| SCHEMBL18343685 | 0.77 | HSP90AB1 (0.44) | ALDH1A1HPGDSMN1; SMN2KDM4EFFAR4 | |
| SCHEMBL10389241 | 0.77 | MAPK1 (0.41) | ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL28715240 | 0.77 | MAPK1 (0.41) | ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113272303-B | Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method and medical application thereof | 上海拓界生物医药科技有限公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-118414332-A | (S) -2- (2-methylazetidin-1-yl) pyrimidine derivatives and pharmaceutical compositions containing the same | 株式会社LG化学 | 2024-07-30 | — | — | CN | disclosed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2022-10-20 | — | — | US | disclosed |
| CN-110023292-B | Apoptosis inhibitors | 北京生命科学研究所 | 2022-10-04 | — | — | CN | disclosed |
| US-20220073521-A1 | PYRIMIDINE AND FIVE-MEMBERED NITROGEN HETEROCYCLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | TUOJIE BIOTECH (SHANGHAI) CO., LTD. (CN) | 2022-03-10 | — | — | US | disclosed |
| US-20220073521-A1 | PYRIMIDINE AND FIVE-MEMBERED NITROGEN HETEROCYCLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | TUOJIE BIOTECH (SHANGHAI) CO., LTD. (CN) | 2022-03-10 | — | — | US | disclosed |
| EP-1383743-A4 | DUAL INHIBITORS OF PDE 7 AND PDE 4 | BRISTOL MYERS SQUIBB CO (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005105801-A1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
| EP-1397142-A4 | PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 | BRISTOL MYERS SQUIBB CO (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1397142-A2 | PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 | Bristol-Myers Squibb Company (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-1383743-A2 | DUAL INHIBITORS OF PDE 7 AND PDE 4 | Bristol-Myers Squibb Company (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030162802-A1 | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-28 | — | — | US | disclosed |
| US-20030104974-A1 | Dual inhibitorsof PDE 7 and PDE 4 | BRISTOL-MYERS SQUIBB COMPANY | 2003-06-05 | — | — | US | disclosed |
| WO-2002102313-A2 | PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002088079-A2 | DUAL INHIBITORS OF PDE 7 AND PDE 4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002088080-A2 | DUAL INHIBITORS OF PDE 7 AND PDE 4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11725000-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | ALDH1A1 550/4885HPGD 208/4885SMN1; SMN2 1698/4885 |
| US-20030104974-A1 | Dual inhibitorsof PDE 7 and PDE 4 | PDE4A, PDE4B, PDE7B | ALDH1A1 1814/4885HPGD 2653/4885SMN1; SMN2 4299/4885 |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | ALDH1A1 233/4885HPGD 218/4885SMN1; SMN2 4377/4885 |
| US-20220073521-A1 | PYRIMIDINE AND FIVE-MEMBERED NITROGEN HETEROCYCLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | PTPN5, PTPN11, PTPN1 | ALDH1A1 1766/4885HPGD 786/4885SMN1; SMN2 3965/4885 |
| US-20030162802-A1 | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 | PDE7A, PDE7B, PDE3A | ALDH1A1 475/4885HPGD 469/4885SMN1; SMN2 3040/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | ALDH1A1 233/4885HPGD 218/4885SMN1; SMN2 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.